Peter B Dirks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/343923/publications.pdf

Version: 2024-02-01

22153 12597 27,802 157 59 132 citations h-index g-index papers 172 172 172 32010 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	30.7	53
2	Fronto-Parietal and White Matter Haemodynamics Predict Cognitive Outcome in Children with Moyamoya Independent of Stroke. Translational Stroke Research, 2022, 13, 757-773.	4.2	3
3	Neurovascular Manifestations in Pediatric Patients With Hereditary Haemorrhagic Telangiectasia. Pediatric Neurology, 2022, 129, 24-30.	2.1	2
4	Building the ecosystem for pediatric neuroâ€oncology care in Pakistan: Results of a 7â€year long twinning program between Canada and Pakistan. Pediatric Blood and Cancer, 2022, 69, e29726.	1.5	4
5	Single-cell chromatin profiling of the primitive gut tube reveals regulatory dynamics underlying lineage fate decisions. Nature Communications, 2022, 13, .	12.8	10
6	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. Neuro-Oncology, 2022, 24, i97-i97.	1.2	0
7	GCT-22. OUTCOMES OF CHILDREN WITH LOCALIZED AND METASTATIC GERMINOMA TREATED WITH CHEMOTHERAPY FOLLOWED BY RADIATION THERAPY WITHOUT PRIMARY TUMOR BOOST. Neuro-Oncology, 2022, 24, i59-i59.	1.2	2
8	Abstract LB188: Identification of intrinsic molecular vulnerabilities in inherited and treatment-related hypermutant patient-derived glioma cell line models. Cancer Research, 2022, 82, LB188-LB188.	0.9	0
9	Deep venous communication in vein of Galen malformations: incidence, Imaging, and Implications for treatment. Journal of NeuroInterventional Surgery, 2021, 13, 290-293.	3.3	8
10	Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity. Nature Cancer, 2021, 2, 157-173.	13.2	147
11	Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. ELife, 2021, 10, .	6.0	45
12	Surgical management of pediatric rolandic arteriovenous malformations: a single-center case series. Journal of Neurosurgery: Pediatrics, 2021, 27, 62-68.	1.3	1
13	PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nature Communications, 2021, 12, 979.	12.8	77
14	The DEAD-box helicase DDX56 is a conserved stemness regulator in normal and cancer stem cells. Cell Reports, 2021, 34, 108903.	6.4	9
15	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
16	The white matter is a pro-differentiative niche for glioblastoma. Nature Communications, 2021, 12, 2184.	12.8	37
17	Pediatric multicompartmental trigeminal schwannoma: illustrative case. Journal of Neurosurgery Case Lessons, 2021, 1, .	0.3	O
18	Distinct Clinical and Radiographic Phenotypes in Pediatric Patients With Moyamoya. Pediatric Neurology, 2021, 120, 18-26.	2.1	18

#	Article	IF	CITATIONS
19	Clinical and Angioarchitectural Features of Hemorrhagic Brain Arterio-Venous Malformations in Adults and Children: Contrasts and Implications on Outcome. Neurosurgery, 2021, 89, 645-652.	1.1	3
20	Long Vascular Sheaths for Transfemoral Neuroendovascular Procedures in Children. Neurointervention, 2021, 16, 149-157.	0.8	2
21	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. Journal of Neuro-Oncology, 2021, 155, 63-70.	2.9	6
22	Improving long-term outcomes in pediatric torcular dural sinus malformations with embolization and anticoagulation: a retrospective review of The Hospital for Sick Children experience. Journal of Neurosurgery: Pediatrics, 2021, 28, 469-475.	1.3	6
23	Pan-cancer analysis of non-coding transcripts reveals the prognostic onco-lncRNA HOXA10-AS in gliomas. Cell Reports, 2021, 37, 109873.	6.4	13
24	Re-evaluating surgery and re-irradiation for locally recurrent pediatric ependymoma – a multi-institutional study. Neuro-Oncology Advances, 2021, 3, vdab158.	0.7	5
25	EPCO-22. INHERITED POLYMORPHISM IN CHROMOSOME 8Q24 COOPERATES WITH MUTANT IDH1, Trp53 AND ATRX LOSS TO INDUCE LOW-GRADE GLIOMA. Neuro-Oncology, 2021, 23, vi6-vi6.	1.2	O
26	STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY. Neuro-Oncology, 2021, 23, vi26-vi26.	1.2	0
27	TMOD-18. DIRECT IN VIVO CRISPR SCREEN IDENTIFIES COOPERATING TUMOR SUPPRESSORS THAT DRIVE PROGRESSION OF IDH1-MUTANT LOW-GRADE GLIOMA TO AGGRESSIVE GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi219-vi219.	1.2	O
28	264. A 20-year Study of Intracranial Pyogenic Complications of Sinusitis in Children. Open Forum Infectious Diseases, 2021, 8, S238-S238.	0.9	0
29	Successful management of symptomatic hydrocephalus using a temporary external ventricular drain with or without endoscopic third ventriculostomy in pediatric patients with germinoma. Journal of Neurosurgery, 2021, , 1-6.	1.6	2
30	Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?. Journal of Pediatric Hematology/Oncology, 2020, 42, e248-e250.	0.6	10
31	Predicting Ischemic Risk Using Blood Oxygen Level–Dependent MRI in Children with Moyamoya. American Journal of Neuroradiology, 2020, 41, 160-166.	2.4	12
32	GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nature Communications, 2020, 11, 4205.	12.8	130
33	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	О
34	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
35	Three-Dimensional Computed Tomography Reconstruction Unmasks Shunt Disconnection in a Child. Canadian Journal of Neurological Sciences, 2020, 47, 826-827.	0.5	1
36	Treatment Strategies and Related Outcomes for Brain Arteriovenous Malformations in Children: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2020, 215, 472-487.	2.2	14

#	Article	IF	CITATIONS
37	Locations, associations and temporal evolution of intracranial arterial infundibular dilatations in children. Journal of NeuroInterventional Surgery, 2020, 12, 495-498.	3.3	4
38	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. Clinical Cancer Research, 2020, 26, 2457-2460.	7.0	8
39	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	16.8	244
40	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	1.2	39
41	Factors Contributing to Major Neurological Complications From Vein of Galen Malformation Embolization. JAMA Neurology, 2020, 77, 992.	9.0	26
42	Roadmap for the Emerging Field of Cancer Neuroscience. Cell, 2020, 181, 219-222.	28.9	182
43	Fractional Flow on TOF-MRA as a Measure of Stroke Risk in Children with Intracranial Arterial Stenosis. American Journal of Neuroradiology, 2020, 41, 535-541.	2.4	4
44	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell, 2020, 181, 1329-1345.e24.	28.9	79
45	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2+ Granule Neuron Precursor. Cell Reports, 2020, 31, 107511.	6.4	35
46	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. Neuro-Oncology, 2020, 22, iii363-iii363.	1.2	1
47	Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. Journal of Clinical Investigation, 2020, 130, 3069-3086.	8.2	15
48	RARE-09. PRESERVATION OF ENDOCRINE FUNCTION AFTER OMMAYA RESERVOIR INSERTION IN CHILDREN WITH CYSTIC CRANIOPHARYNGIOMA. Neuro-Oncology, 2020, 22, iii443-iii443.	1.2	0
49	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	1.2	0
50	STEM-29. THE HISTONE VARIANT macroH2A2 ORCHESTRATES AN ACTIONABLE CHROMATIN PROGRAM OF STEMNESS IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii202-ii202.	1.2	0
51	ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. Cancer Research, 2019, 79, 4057-4071.	0.9	39
52	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
53	High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Research, 2019, 29, 1211-1222.	5.5	52
54	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. Child's Nervous System, 2019, 35, 861-864.	1.1	9

#	Article	IF	CITATIONS
55	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. Cell Stem Cell, 2019, 25, 433-446.e7.	11.1	56
56	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. Neuro-Oncology, 2019, 21, ii96-ii97.	1.2	0
57	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell, 2019, 35, 782-797.e8.	16.8	143
58	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature, 2019, 572, 67-73.	27.8	293
59	Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. Cell Reports, 2019, 27, 971-986.e9.	6.4	139
60	Making a commitment: neurons refuse cancer's advances. Nature Neuroscience, 2019, 22, 507-508.	14.8	1
61	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
62	Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells. Genes and Development, 2019, 33, 498-510.	5.9	74
63	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer, 2019, 125, 1867-1876.	4.1	49
64	PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2019, 21, vi184-vi185.	1.2	0
65	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
66	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. Cell, 2019, 179, 1330-1341.e13.	28.9	206
67	Stalled developmental programs at the root of pediatric brain tumors. Nature Genetics, 2019, 51, 1702-1713.	21.4	136
68	Gastrointestinal transcription factors drive lineage-specific developmental programs in organ specification and cancer. Science Advances, 2019, 5, eaax8898.	10.3	26
69	Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma. Developmental Cell, 2019, 48, 167-183.e5.	7.0	39
70	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. Neuro-Oncology, 2019, 21, 547-557.	1.2	32
71	Unruptured intracranial aneurysms in children: 18 years' experience in a tertiary care pediatric institution. Journal of Neurosurgery: Pediatrics, 2019, 24, 184-189.	1.3	8
72	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. Cell, 2018, 172, 1050-1062.e14.	28.9	85

#	Article	IF	CITATIONS
73	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	27.8	170
74	Delayed Chronic Subdural Hematoma after Total Cranial Vault Reconstruction for Sagittal Synostosis. Pediatric Neurosurgery, 2018, 53, 200-204.	0.7	3
75	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
76	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i106-i106.	1.2	0
77	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. Neuro-Oncology, 2018, 20, i92-i92.	1.2	0
78	A Feedforward Mechanism Mediated by Mechanosensitive Ion Channel PIEZO1 and Tissue Mechanics Promotes Glioma Aggression. Neuron, 2018, 100, 799-815.e7.	8.1	241
79	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. Neuro-Oncology, 2018, 20, i117-i117.	1.2	0
80	Breath-Hold Blood Oxygen Level–Dependent MRI: A Tool for the Assessment of Cerebrovascular Reserve in Children with Moyamoya Disease. American Journal of Neuroradiology, 2018, 39, 1717-1723.	2.4	55
81	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	21.4	112
82	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
83	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	28.9	596
84	Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature, 2017, 549, 227-232.	27.8	321
85	ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells. Cell Stem Cell, 2017, 21, 209-224.e7.	11.1	150
86	Intracranial artery to artery spontaneous revascularization in a child. Child's Nervous System, 2017, 33, 2035-2038.	1.1	4
87	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
88	Brain Tumor Stem Cells Remain in Play. Journal of Clinical Oncology, 2017, 35, 2428-2431.	1.6	54
89	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
90	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma Journal of Clinical Oncology, 2017, 35, 10503-10503.	1.6	0

#	Article	IF	Citations
91	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. Neuro-Oncology, 2016, 18, iii94.1-iii94.	1.2	0
92	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
93	Is jugular bulb stenosis in vein of Galen aneurysmal malformation associated with bony remodeling of the jugular foramina?. Journal of Neurosurgery: Pediatrics, 2016, 18, 92-96.	1.3	4
94	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. Journal of Clinical Neuroscience, 2016, 34, 169-176.	1.5	29
95	Association Between Prolonged Seizures and Malignant Middle Cerebral Artery Infarction in Children With Acute Ischemic Stroke. Pediatric Neurology, 2016, 64, 44-51.	2.1	16
96	Global chromatin architecture defines functional cancer hierarchies. Cell Cycle, 2016, 15, 2093-2094.	2.6	3
97	Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell, 2016, 29, 859-873.	16.8	169
98	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
99	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
100	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	1.6	692
101	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
102	Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 851-856.	7.1	321
103	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244
104	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262.	21.4	306
105	Preclinical target validation using patient-derived cells. Nature Reviews Drug Discovery, 2015, 14, 149-150.	46.4	46
106	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
107	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular Cancer Therapeutics, 2015, 14, 2560-2568.	4.1	55
108	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell, 2015, 163, 1515-1526.	28.9	1,339

#	Article	IF	Citations
109	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell, 2015, 28, 715-729.	16.8	90
110	Patterns of Cerebral Ischemia in Children With Moyamoya. Pediatric Neurology, 2015, 52, 65-72.	2.1	28
111	Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget, 2015, 6, 21718-21729.	1.8	26
112	Cell Surface Profiling Using High-Throughput Flow Cytometry: A Platform for Biomarker Discovery and Analysis of Cellular Heterogeneity. PLoS ONE, 2014, 9, e105602.	2.5	65
113	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. Cancer Discovery, 2014, 4, 1198-1213.	9.4	55
114	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature Genetics, 2014, 46, 39-44.	21.4	167
115	Pediatric awake craniotomy and intra-operative stimulation mapping. Journal of Clinical Neuroscience, 2014, 21, 1891-1894.	1.5	60
116	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. Cancer Cell, 2014, 26, 33-47.	16.8	241
117	Selective Calcium Sensitivity in Immature Glioma Cancer Stem Cells. PLoS ONE, 2014, 9, e115698.	2.5	23
118	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
119	A Tumorigenic MLL-Homeobox Network in Human Glioblastoma Stem Cells. Cancer Research, 2013, 73, 417-427.	0.9	77
120	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
121	Cancer stem cells: an evolving concept. Nature Reviews Cancer, 2012, 12, 133-143.	28.4	1,055
122	Invitation to a second round. Nature, 2010, 466, 40-41.	27.8	49
123	Brain tumor stem cells: The cancer stem cell hypothesis writ large. Molecular Oncology, 2010, 4, 420-430.	4.6	127
124	Multipotent CD15+ Cancer Stem Cells in <i>Patched-1</i> i>–Deficient Mouse Medulloblastoma. Cancer Research, 2009, 69, 4682-4690.	0.9	166
125	Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain Tumors. Cancer Cell, 2009, 16, 533-546.	16.8	207
126	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Reviews Drug Discovery, 2009, 8, 806-823.	46.4	755

#	Article	IF	Citations
127	MicroRNAs and Parallel Stem Cell Lives. Cell, 2009, 138, 423-424.	28.9	18
128	Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens. Cell Stem Cell, 2009, 4, 568-580.	11,1	881
129	Brain Cancer Stem Cells: A Level Playing Field. Cell Stem Cell, 2009, 5, 468-469.	11.1	20
130	Separating Stem Cells by Flow Cytometry: Reducing Variability for Solid Tissues. Cell Stem Cell, 2009, 5, 579-583.	11.1	58
131	New drugs for brain tumors? Insights from chemical probing of neural stem cells. Medical Hypotheses, 2009, 72, 683-687.	1.5	28
132	Cancer's source in the peripheral nervous system. Nature Medicine, 2008, 14, 373-375.	30.7	10
133	Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer. Journal of Clinical Oncology, 2008, 26, 2916-2924.	1.6	164
134	Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 139-152.	4.0	67
135	THE HISTORY OF NEUROSURGERY AT THE HOSPITAL FOR SICK CHILDREN IN TORONTO. Neurosurgery, 2007, 61, 612-625.	1.1	15
136	Cancer Stem Cells: At the Headwaters of Tumor Development. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 175-189.	22.4	136
137	Chemical genetics reveals a complex functional ground state of neural stem cells. Nature Chemical Biology, 2007, 3, 268-273.	8.0	153
138	Bmi1 and Cell of Origin Determinants of Brain Tumor Phenotype. Cancer Cell, 2007, 12, 295-297.	16.8	22
139	Brain Tumor Stem Cells: Identification and Concepts. Neurosurgery Clinics of North America, 2007, 18, 31-38.	1.7	53
140	Brain tumor stem cells. Biology of Blood and Marrow Transplantation, 2005, 11, 12-13.	2.0	16
141	Cerebral Sinovenous Thrombosis Post Head Injury - 10 Year Experience in Children Blood, 2005, 106, 4132-4132.	1.4	0
142	Cancer stem cells in nervous system tumors. Oncogene, 2004, 23, 7267-7273.	5.9	670
143	Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.	27.8	6,758
144	Identification of a cancer stem cell in human brain tumors. Cancer Research, 2003, 63, 5821-8.	0.9	3,675

#	Article	IF	CITATION
145	The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. Journal of Neuro-Oncology, 2001, 51, 219-229.	2.9	74
146	Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective. Journal of Neuro-Oncology, 2001, 51, 205-218.	2.9	15
147	Glioma migration: clues from the biology of neural progenitor cells and embryonic CNS cell migration., 2001, 53, 203-212.		42
148	Coâ€expression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells. International Journal of Developmental Neuroscience, 1999, 17, 503-515.	1.6	79
149	Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells. Journal of Neuro-Oncology, 1998, 40, 137-150.	2.9	56
150	The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells. Oncogene, 1998, 17, 867-876.	5.9	46
151	Cyclin and Cyclin-Dependent Kinase Expression in Human Astrocytoma Cell Lines. Journal of Neuropathology and Experimental Neurology, 1997, 56, 291-300.	1.7	34
152	Current Concepts in Neuro-Oncology: The Cell Cycle-A Review. Neurosurgery, 1997, , .	1.1	0
153	Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogene, 1997, 15, 2037-2048.	5.9	61
154	Activity of the Retinoblastoma Family Proteins, pRB, p107, and p130, during Cellular Proliferation and Differentiation. Critical Reviews in Biochemistry and Molecular Biology, 1996, 31, 237-271.	5.2	117
155	Suprateutorial primitive neuroectodermal tumors in children. Journal of Neuro-Oncology, 1996, 29, 75-84.	2.9	114
156	Expression of stromelysin 1 in human astrocytoma cell lines. Journal of Neuro-Oncology, 1996, 30, 181-8.	2.9	15
157	The Functional Genomic Circuitry of Human Glioblastoma Stem Cells. SSRN Electronic Journal, 0, , .	0.4	O